TY - JOUR
T1 - Immunogenicity of a recombinant human immunodeficiency virus (HIV) - Canarypox vaccine in HIV-seronegative Ugandan volunteers
T2 - Results of the HIV network for prevention trials 007 vaccine study
AU - Cao, Huyen
AU - Kaleebu, P.
AU - Hom, D.
AU - Flores, J.
AU - Agrawal, D.
AU - Jones, N.
AU - Serwanga, J.
AU - Okello, M.
AU - Walker, C.
AU - Sheppard, H.
AU - El-Habib, R.
AU - Klein, M.
AU - Mbidde, E.
AU - Mugyenyi, P.
AU - Walker, B.
AU - Ellner, J.
AU - Mugerwa, R.
PY - 2003/3/15
Y1 - 2003/3/15
N2 - In the first preventative human immunodeficiency virus (HIV) vaccine study to be carried out in Africa, 40 HIV-seronegative Ugandan volunteers were randomly assigned to receive a canarypox vector containing HIV-1 clade B (env and gag-pro) antigens (ALVAC-HIV; n = 20), control vector containing the rabies virus glycoprotein G gene (n = 10), or saline placebo (n = 10). Cytotoxic T lymphocyte activity against target cells expressing clade A, B, and D antigens was assessed using standard chromium-release and confirmatory interferon-γ enzyme-linked immunospot (ELISPOT) assays. Neutralizing antibody responses to cell line-adapted strains and primary isolates in all 3 clades were also tested. Twenty percent of vaccine recipients generated detectable cytolytic responses to either Gag or Env, and 45% had vaccine-induced HIV-specific CD8+ T cell responses, as measured by the ELISPOT assay. In contrast, only 5% of the control group had vaccine-specific responses. Neutralizing antibodies against primary and laboratory-adapted HIV-1 clade B strains were seen in 10% and 15% of vaccine recipients, respectively, but responses against clades A and D were not detected. Although the immunogenicity of this clade B-based vaccine was low, ALVAC-HIV elicited CD8+ T cell responses with detectable cross-activity against clade A and D antigens in a significant proportion of vaccine recipients.
AB - In the first preventative human immunodeficiency virus (HIV) vaccine study to be carried out in Africa, 40 HIV-seronegative Ugandan volunteers were randomly assigned to receive a canarypox vector containing HIV-1 clade B (env and gag-pro) antigens (ALVAC-HIV; n = 20), control vector containing the rabies virus glycoprotein G gene (n = 10), or saline placebo (n = 10). Cytotoxic T lymphocyte activity against target cells expressing clade A, B, and D antigens was assessed using standard chromium-release and confirmatory interferon-γ enzyme-linked immunospot (ELISPOT) assays. Neutralizing antibody responses to cell line-adapted strains and primary isolates in all 3 clades were also tested. Twenty percent of vaccine recipients generated detectable cytolytic responses to either Gag or Env, and 45% had vaccine-induced HIV-specific CD8+ T cell responses, as measured by the ELISPOT assay. In contrast, only 5% of the control group had vaccine-specific responses. Neutralizing antibodies against primary and laboratory-adapted HIV-1 clade B strains were seen in 10% and 15% of vaccine recipients, respectively, but responses against clades A and D were not detected. Although the immunogenicity of this clade B-based vaccine was low, ALVAC-HIV elicited CD8+ T cell responses with detectable cross-activity against clade A and D antigens in a significant proportion of vaccine recipients.
UR - http://www.scopus.com/inward/record.url?scp=0037444039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037444039&partnerID=8YFLogxK
U2 - 10.1086/368020
DO - 10.1086/368020
M3 - Article
C2 - 12660934
AN - SCOPUS:0037444039
SN - 0022-1899
VL - 187
SP - 887
EP - 895
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -